false
Catalog
The Liver Meeting 2019
Assessing and Addressing Liver Fibrosis in the All ...
Assessing and Addressing Liver Fibrosis in the Allograft
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Thank you very much everyone, and you are welcome to look. It is extensive sessions on allograft. I'm going to talk to you today, like Venus says, on assessment and staging of liver fibrosis in allograft. These are my responsibilities. I don't need to tell the public, and we have had many uses, what is a composition for inspiration, what is the real, what you must inspire, and what you must not inspire. But there is no question that inspiration and children have made behavior out of a flurry of events, but we are still learning about the allograft effect in the future, and we have had a lot of discussion for allograft mechanisms. I want to show you an inspiration that starts my important people allograft behavior, and this was developed over 20 years ago from Birmingham, and shows developing allograft behavior in protocol biopsies. Now, this is a group of children who are on cyclosporine monotherapy, and so we've done protocol biopsies at 1, 5 and 10 years, and I don't think it shows very well, but you can see that bar were normal biopsies, and in fact, over time, these biopsies became more abnormal, with an association of hepatitis and fibrosis. And these developments were shared from units around the world, from Groningen, from Chicago, there was a period of graft hepatitis, and the only risk factor we use in Birmingham The Groningen group also wrote that the development of this fibrosis is more efforts, so not only does it increase with time, but the relationships of the fibrosis change, so it's more extreme to get portal fibrosis first, strive for sinusoidal and centrelobular fibrosis during the period. And we have Jake in the street, so it's always very difficult to talk about writing systems and the history when you're actually one of the life information, but for all the studies I'm going to talk about, we use the semi-computational writing fibrosis, the very important things, from man to serosus. But a University group has developed semi-computational writing. which is about the Venturi system, which, again, Jake chose during his conversation, which is a more communicative way to look at the fibrosizer, and again, to show you all the data, the Brussel group has shown that. In that I am general ways, when I chose to write the campaign craft, environmentally in the biopsies years, I thought the campaigning might take fibrosis. I might be right, I might not, but this is what we felt at first, is that the campaigning craft came first, and the fibrosis came second, but the other members, and most of this is the Brusgau and the Gronegain organisations, in fact, other factors for graft fibrosis were resolved. It was generally in partial grafts, in delivery grafts, generally in those having maximum ischemic times and those having years organizations, who realize that other employees might from the sliad from Groningen that the increase in fibrosis will be with time. So, was this statement related to the statement from our group involved in the craft? Many of the founding members are in the association, so you'll see how fine and dandy we all are. And, Jake, we're common health on that day, I believe, right now, from the shots of Jake about how they're pretty good about how the activity could be on trans the world between Asia and Europe, but I must say one thing about the direction, they are absolutely interesting in relation to the craft. or bryo-vascula environments that mean efforts. So it was quite a useful group in a number of ways. Therefore, 12 of our group of graffiti organizations have included data for the research around the world, and we were getting £365. So, really, before these, just a few points. They were very fine. They were involved in discussing them during two. And because he studied backwards going backwards, the majority of these fronts were allowed to scrutinize the success. So this is a very important slide. This shows you that fibrosis is welcoming, so there are different numbers of children is part of the group. Those who remember that the responsibility was 10 years, some of the children get biopsies of 5 years and some of the children get 15 years. And I think you can see that, as demonstrated in the lonely room studies, there is an increase for the fibrosis with time, with the majority of children having peri-biopsies. and a few of these children developed cirrhosis. So, here are all the publishers on those particular points. But we've also had amazing hospitals. So, this is the one of the children. There are 100 children that we have 5, 10 and 15 years of biopsy, but you can see that the image is quite fine, that a few of the children have fibrosis at 5 and 10 years. But there is a group that is very important, there is a group of children about 20% who have normal histologies throughout. And I hope these children should be confident and maybe they don't need to be for immune pathways, or I hope you can say maybe the kids who have been should for immune pathways and do not have histological developments. And I hope we can But it is not a one time system. The fibrosis can improve, and in this slide we look at the change in the fibrosis framers. I remember, it's a very very conversation, so it was a conversation that they would have three for as many years and one for as many years or whatever, but there is a group of years which has increased the fibrosis, again by 20%, so it was not a street once. And I think what's really important is that they didn't feel it was a big deal after 15 years, and so once the fibrosis developed, it was very safe. There were one or two years that have had cirrhosis and responsibility, but especially they were very safe. So, what were the factors involved in this? As I told you, auto animals were very important to us with graft hepatitis, and so the years that have had And those who were more likely to be increased were those who So, in association, fibrosis was increasing, but after 10 years. and it shows that Lode's steroidae are involved in their differentiation. and so forth. So I think it's important, and I think, to look at, are we, can we come to the craft in different ways? Can we approach them in amazing ways? What is our biography society? So, I've commented on auto animals for flowr and here is data from our craft group which shows that auto animals are important over 5 and 10 years, but the program of the design is not obvious, but the programs are trustworthy? Currently, the programs are fiduciary. We've talked a lot about DSA antibodies here the last day. I'm no expert, but you've heard the full from Jake and from Jackie how important they are and how well they have been connected to them. can achieve with the speakers. that you would have to be very grateful from where you put your prog, because many of the meetings were serious with the fibroscan, but they may not feel that the child would if they were able to have good meetings with the fibroscan, it communicated well with the histology, so perhaps surely there were ways of investment. And of course, it is now increasing for a population of using the multiscan flowr, and this photographs shows you how the multiscan can produce with steatosis. It is indeed very effective to use ways of thinking and, at least, copper in the flow. It has been used retrospectively. and this slide looks at some future data using the chronic last of the CT1 and there was a good severity between biopsies Now, although this is very good because it is very good, we can proceed with Jake and all the candidates that are proceeding with them into the parametric MRI scanner and the calculations that you will you want to be offered with the software, but it is amazing that not all are to learn very well which is amazing without anesthetic connection. Therefore, in most of our workshops, But I thought I would show you some data from Birmysgol CNI inhibitors plus steroid in the latest publication, and we have given a link with the two publications of discussions. In the first column is the monotherapy is the last responsibility reported in 2006. In column two these are with combination therapy, perhaps with cacrolimus and prednisolone or cyclosporon and prednisolone. That's it using the same responsibility system for fibrosi as I've written, and in Wales. We have responsibility for both groups of children. Obviously, the limitations of responsibility were interesting, rather than both historical experiences. I believe the only change is But I saw it as dramatic. for campaigning efforts, and you can see that the most However, that effect is not dramatic on the fibrosis. There was a slight improvement in the heritage from the 5 year interviews, but really no difference at 10 years. So, in order to write that, we discovered an environment of graft hepatitis in the heritage of interviews, with an interview in histology, and the other observational surveys, and an environment of fibrosis at 5 years, but not at 10 years, which means that the immunol increasing pathways are effective for interview hepatitis, therefore So, to our course, we have translated in a large social and environmental study, the great responsibility of graph fibrosis and children after transport, and increase them over time, but also its general equality at 15, maybe to 20 years. And quite importantly, at the moment where we have not really used a way of non-active fibers. So we have to tell you, maybe on the last day, we obviously need To a gathering, thank you all.
Video Summary
The speaker discusses the assessment and staging of liver fibrosis in allografts, focusing on the impact of various factors on the development of fibrosis over time. They highlight the importance of monitoring children post-transplantation for signs of fibrosis progression, showcasing data from protocol biopsies performed at different intervals. The presentation emphasizes the role of autoantibodies and immunomodulatory pathways in graft hepatitis and fibrosis development. Insights from studies on different treatment regimens suggest limited impact on fibrosis progression. The speaker underscores the need for continued research to improve understanding and management of fibrosis in allograft recipients.
Asset Caption
Presenter: Deirdre A. Kelly
Keywords
liver fibrosis
allografts
assessment
children post-transplantation
autoantibodies
research
×
Please select your language
1
English